Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct-Dec;13(4):636-642.
doi: 10.4103/aer.AER_126_19. Epub 2019 Dec 16.

Dexmedetomidine Compared to Remifentanil Infusion as Adjuvant to Sevoflurane Anesthesia during Laparoscopic Sleeve Gastrectomy

Affiliations

Dexmedetomidine Compared to Remifentanil Infusion as Adjuvant to Sevoflurane Anesthesia during Laparoscopic Sleeve Gastrectomy

Jehan M E Hamed et al. Anesth Essays Res. 2019 Oct-Dec.

Abstract

Objectives: Evaluation of postoperative (PO) analgesic effects of intraoperative (IO) Dexmedetomidine (DEX) compared to remifentanil (REMI) infusions during sevoflurane anesthesia for laparoscopic gastric sleeve surgery.

Patients and methods: One hundred and thirty-two patients with body mass index >35 kg.m-2 and ASA Grades II or III were randomly divided into group R received REMI infusion (6-18 μg.kg-1.h-1) and Group D received DEX infusion (0.2-0.5 μg.kg-1.h-1) after tracheal intubation till before stoppage of inhalational anesthetic. Heart rate and mean arterial pressure were noninvasively monitored during and after surgery. Emergence time, time until postanesthetic care unit transfer, and total operating room (OR) time was recorded. PO shoulder-tip pain and wound pain scores were recorded and rescue analgesia was provided as 50 mg pethidine intramuscular injection. Occurrence of PO nausea and vomiting (PONV) and frequency of the need for antiemetic therapy were recorded. Primary study outcome was the ability of the study infusions to reduce consumption of PO pethidine down to one dose during 24-hr PO.

Results: IO use of REMI or DEX infusion allowed hemodynamic control to surgical stresses with nonsignificant difference between both infusions. REMI infusion insured significantly rapid recovery and short OR times but required larger volume of sevoflurane during surgery and proper PO follow-up for pain and PONV. DEX infusion significantly improved control of PO pain with a larger number of patient requested rescue analgesia only once, reduced the dose of PO analgesia, reduced the frequency of PONV, and the need for antiemetic therapy.

Conclusion: REMI or DEX infusion as IO adjuvant to general anesthesia is appropriate option to achieve hemodynamic control of surgical stresses and to improve perioperative outcomes. REMI infusion may be preferred for its induced rapid recovery and short OR time, whereas DEX infusion may be chosen for its improved control of PO pain and reduction of PO analgesia and frequency of PONV.

Keywords: Bariatric surgery; dexmedetomidine infusion; perioperative outcomes; remifentanil infusion; sevoflurane.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Consort flow sheet
Figure 2
Figure 2
Mean postoperative numeric rating scale score for shoulder-tip pain determined throughout 24-h postoperative in patients of both groups
Figure 3
Figure 3
Patients' distribution according to the number of requests of rescue analgesia
Figure 4
Figure 4
Mean number of requests of rescue analgesia and dose used by patients of both groups

Similar articles

Cited by

References

    1. Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–7. - PubMed
    1. Goossens GH. The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10:207–15. - PMC - PubMed
    1. Gletsu-Miller N, Shevni N, Manatunga A, Lin E, Musselman D. A multidimensional analysis of the longitudinal effects of roux en y gastric bypass on fatigue: An association with visceral obesity. Physiol Behav. 2019;209:112612. - PubMed
    1. Benaiges D, Goday A, Pedro-Botet J, Más A, Chillarón JJ, Flores-Le Roux JA. Bariatric surgery: To whom and when? Minerva Endocrinol. 2015;40:119–28. - PubMed
    1. Kamata M, Tobias JD. Remifentanil: Applications in neonates. J Anesth. 2016;30:449–60. - PubMed